SCHEMBL21137853

SCHEMBL21137853

CCCC(=O)NC1C(C)OC(COC(C)=O)C(OC(C)=O)C1OC(C)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.51
▸ NR3C1 P04150 1/20 0.46
▸ FYN P06241 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ CA12 O43570 6/20 0.45
▸ CA1 P00915 6/20 0.45
▸ CA2 P00918 6/20 0.45
▸ CA9 Q16790 6/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ THRB P10828 2/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ POLB P06746 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21058368 0.88 LMNA (0.65) LMNANR3C1FYNADRA2AADORA3
SCHEMBL21058373 0.88 LMNA (0.51) LMNANR3C1FYNADRA2AADORA3
SCHEMBL25957762 0.88 LMNA (0.65) LMNANR3C1FYNADRA2AADORA3
SCHEMBL30032874 0.88 LMNA (0.65) LMNANR3C1FYNADRA2AADORA3
SCHEMBL21138671 0.88 LMNA (0.65) LMNANR3C1FYNADRA2AADORA3
SCHEMBL25957810 0.88 LMNA (0.51) LMNANR3C1FYNADRA2AADORA3
SCHEMBL19733727 0.86 LMNA (0.52) LMNANR3C1FYNADRA2AADORA3
SCHEMBL19733703 0.86 LMNA (0.47) LMNANR3C1FYNADRA2AADORA3
SCHEMBL23626630 0.85 LMNA (0.57) LMNANR3C1FYNADRA2AADORA3
SCHEMBL25480951 0.85 LMNA (0.57) LMNANR3C1FYNADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA LMNA 2743/4885NR3C1 880/4885FYN 1694/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA LMNA 2743/4885NR3C1 880/4885FYN 1694/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA LMNA 2743/4885NR3C1 880/4885FYN 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback